AUTHORS
Michelle Yu Zhang, MD, Megan Othus, PhD2, Sarah Peterson, MD, MPH3, Kathryn (Katie) D. Russell, ARNP4, Carole Shaw5, Rutu Vyas6, Suravi Raychaudhuri, MD7, Anna Halpern, MD8, Ryan D. Cassaday, MD9, Marianne E Dubard-Gault10, Sioban Keel, MD11, Bart L Scott, MD12, Roland Bruno Walter, MD, PhD, MS13, Paul Hendrie, MD, PHD14, Jacob Appelbaum, MD/PhD15, Mary-Elizabeth Percival, MD16
AFFILIATIONS
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 University of Washington, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
10 Swedish Cancer Institute, Seattle, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
14 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
16 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
ABSTRACT
Background: Li-Fraumeni Syndrome (LFS) is a rare cancer predisposition syndrome associated with sarcoma, breast cancer, and leukemia. LFS can be diagnosed via clinical criteria or detection of a pathogenic germline TP53 variant. Limited data exist for patients with LFS and hematologic malignancies, including development of therapy-related myeloid neoplasms and outcomes after allogeneic hematopoietic cell transplantation (HCT). Prior studies have suggested particularly poor outcomes in patients with acute myeloid leukemia (AML) and ALL. We characterized a single center cohort of patients with LFS diagnosed with myeloid neoplasms or ALL.
Methods: We utilized an institutional database from University of Washington/Fred Hutchinson Cancer Center to retrospectively identify patients with LFS and myeloid neoplasms or ALL between 2010 and 2026. LFS diagnosis was made clinically (n=5) or via pathogenic germline variant (n=16); these included LFS-like syndrome (n=2) and mosaic LFS (n=1). Prior solid tumors, prior chemotherapy/radiation, cytogenetics, molecular testing, HCT regimens, family history, and survival outcomes were obtained from the database or abstracted from the medical record. Given a limited sample size, univariate associations were evaluated using cause-specific models (for time to transplant) and Cox regression (for overall survival [OS]).
Results: Among the 21 patients, the median age at diagnosis of first hematologic malignancy was 49 (range 3-73) years; three were diagnosed at age <18, all with ALL. Diagnoses included ALL (n=6, 29%), AML (n=4, 19%), acute promyelocytic leukemia (n=1, 5%), essential thrombocythemia (n=3, 14%), or myelodysplastic syndrome (MDS; n=7, 33%). Hypodiploid karyotype occurred exclusively in all 6 patients with ALL; 6 patients had complex karyotype, 7 monosomal karyotype, and 6 loss of 17p/monosomy 17. Ten patients (48%) had prior solid tumors; of these, 8 had received prior chemotherapy/radiation, and karyotype was unfavorable in half (4 complex, 1 hypodiploid). Most (n=9) patients with prior solid tumors developed myeloid neoplasms.
Median OS for the entire cohort was 3.7 years (CI 1.2 years – not reached). In univariate regression across all patients, hypodiploid karyotype (all of whom had ALL) was associated with improved OS (HR 0.09, 95% CI 0.01-0.78). Decreased OS was associated with prior solid tumor (HR 4.26, 95% CI 1.08-16.71), prior chemotherapy/radiation (HR 4.19, 95% CI 1.15-15.22), or meeting classic clinical LFS criteria on chart review (HR 3.70, 95% CI 1.01-13.19).
Twelve patients (57%) underwent HCT for ALL (n=6), AML (n=1), or MDS (n=5); 4 had a prior solid tumor. Conditioning was myeloablative in 6 patients [50%, ALL (n=4), AML (n=1) and MDS (n=1)], reduced intensity in 2 [17%, MDS (n=2)], and non-myeloablative in 4 [33%, MDS (n=2), ALL (n=2)]. TBI was used in 6 patients (median 300 cGy, range 200-1320 cGy). Pre-HCT marrow showed CR in 10 out of 12 patients (2 had MRD detected by flow cytometry/NGS); 2 had persistent disease.
The HR for HCT (time-dependent) was 0.44 (95% CI 0.10-1.93), which did not reach statistical significance. After HCT, 2 patients developed secondary MDS (both had ALL prior); one achieved remission with azacitidine and donor lymphocyte infusion. Following HCT, one patient had relapse and died at 69.2 months of relapsed AML. Three additional patients died post-HCT, one on day +15 (cardiogenic shock), one at +3.4 months (sinusoidal obstructive syndrome), and one at 39.5 months (septic shock in the setting of secondary MDS). Eight patients are alive at last known contact post-HCT with a median follow-up of 3.3 years. There was no significant difference in risk of death between patients with LFS and myeloid malignancies compared to a contemporary 382 patient cohort with somatic TP53-mutated AML/MDS (HR 0.58, 95% CI 0.22-1.55). There was also no significant difference in proportion transplanted (HR 0.75, 95% CI 0.18-3.13).
Conclusions: Our study suggests HCT is feasible in patients with LFS, and select patients can achieve remission and long-term survival. Over half of the cohort underwent HCT; ALL was associated with improved OS, but prior solid tumors, cytotoxic exposure, and meeting classic LFS criteria were associated with worse prognosis. These findings are limited by the small sample size, and future studies with larger cohorts are needed to better characterize hematologic malignancy outcomes after HCT in LFS.
DISCLOSURES
Michelle Yu Zhang, MD: No relevant conflicts of interest to declare.